Cited by 54Asthma and respiratory diseasesAllergic Rhinitis and SensitizationIL-33, ST2, and ILC Pathways

Rapamycin inhibition of eosinophil differentiation attenuates allergic airway inflammation in mice

Open access
Hua, Wen, Liu, Hui, Xia, Li‐Xia, Tian, Bao‐Ping, Huang, Hua‐Qiong, Chen, Zhi‐Yang, Ju, Zhen‐Yu, Li, Wen +2 more·2015·Respirology

Abstract

Background and objective: The mammalian target of rapamycin (mTOR) signalling pathway regulates immune responses, and promotes cell growth and differentiation. Inhibition of mTOR with rapamycin modulates allergic asthma, while the underlying molecular mechanisms remain elusive. Here, we demonstrate that rapamycin, effectively inhibits eosinophil differentiation, contributing to its overall protective role in allergic airway inflammation. Methods: Rapamycin was administered in a mouse model of ovalbumin‐induced allergic airway inflammation, and the eosinophil differentiation was analysed in vivo and in vitro. Results: Rapamycin significantly attenuated allergic airway inflammation and markedly decreased the amount of eosinophils in local airways, peripheral blood and bone marrow, independently of levels of interleukin‐5 (IL‐5). In vitro colony forming unit assay and liquid culture demonstrated that rapamycin directly inhibited IL‐5‐induced eosinophil differentiation. In addition, rapamycin reduced the production of IL‐6 and IL‐13 by eosinophils. Rapamycin was also capable of reducing the eosinophil levels in IL‐5 transgenic NJ.1638 mice, again regardless of the constitutive high levels of IL‐5. Interestingly, rapamycin inhibition of eosinophil differentiation in turn resulted in an accumulation of eosinophil lineage‐committed progenitors in bone marrow. Conclusions: Altogether these results clearly demonstrate a direct inhibitory role of rapamycin in eosinophil differentiation and function, and reemphasize the importance of rapamycin and possibly, mTOR, in allergic airway disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/resp.12554

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Hua, W., Liu, H., Xia, L., Tian, B., Huang, H., Chen, Z., Ju, Z., Li, W., Chen, Z., & Shen, H.
Affiliations
  • Second Affiliated Hospital of Zhejiang University (CN)
  • Department of Respiratory and Critical Care Medicine Second Affiliated Hospital Zhejiang University School of Medicine Hangzhou Zhejiang China
  • Institute of Aging Research Hangzhou Normal University College of Medicine Hangzhou Zhejiang China
Venue
Respirology
Publisher
Wiley
Published
2015-06-04
Volume
20
Issue
7
Pages
1055-1065
ISSN
  • 1323-7799 (ISSN-L)
  • 1440-1843
OpenAlex
W1711531405
Cited by
54
References
27
Citations by year
2026: 1 · 2025: 5 · 2024: 4 · 2023: 4 · 2022: 5 · 2021: 7 · 2020: 9 · 2019: 4 · 2018: 2 · 2017: 8 · 2016: 4 · 2015: 1
FWCI
3.68
Type
journal article
Language
en
Open access
Locations
  • Respirology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Science Foundation for Distinguished Young Scholars of China (30825019)
  • Key Program of National Natural Science Foundation of China (81130001)
  • Program for Zhejiang Leading Team of S&T Innovation (2011R50016)
  • National Key Technologies R&D Program for the 12th Five-year Plan (2012BAI05B01)
  • National Nature Science Foundation of China (81100019)
Topics
  • Health Sciences › Medicine › Physiology › Asthma and respiratory diseases
  • Health Sciences › Medicine › Immunology and Allergy › Allergic Rhinitis and Sensitization
  • Life Sciences › Immunology and Microbiology › Immunology › IL-33, ST2, and ILC Pathways
Keywords
rapamycin, mTOR signaling, eosinophil differentiation, allergic airway inflammation, allergic asthma, ovalbumin-induced airway inflammation, IL-5, interleukin-6, IL-13, eosinophil progenitors, bone marrow, IL-5 transgenic mice
MeSH terms
Animals, Asthma, Cell Differentiation, Disease Models, Animal, Eosinophils, Hypersensitivity, Immunosuppressive Agents, Inflammation, Interleukins, Leukocyte Count, Mice, Inbred BALB C, Mice, Transgenic, Ovalbumin, Signal Transduction, Serine Proteinase Inhibitors, Sirolimus, Mice, TOR Serine-Threonine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review